This type of drug show promise in treating rheumatoid arthritis

Credit: Unsplash+

Rheumatoid arthritis is a chronic autoimmune disease that causes joint inflammation, leading to joint damage and other complications.

While treatments like biological disease-modifying drugs have been effective, they often require unpleasant injections or infusions.

Recently, Janus kinase (JAK) inhibitors, taken orally, have emerged as an alternative. However, concerns lingered about their effectiveness. A new study sheds light on their potential.

Janus kinase inhibitors, or JAK inhibitors, are a newer form of treatment for rheumatoid arthritis. Unlike traditional methods, patients can take these drugs orally.

Previous research demonstrated their efficacy and safety in controlled trials. But questions remained about how well they work in real-world scenarios where patients may have unique characteristics and health issues.

In a multicenter, retrospective study conducted by Japanese researchers, data from 622 rheumatoid arthritis patients treated at seven major university hospitals in Japan were analyzed.

The study aimed to compare the effectiveness and safety of four common JAK inhibitors: tofacitinib, baricitinib, peficitinib, and upadacitinib.

The findings of the study were promising. Approximately one-third of the patients achieved remission, while three out of four reached at least low disease activity. These outcomes demonstrated impressive efficacy, particularly in a real-world context.

Remarkably, over 80% of the patients continued to take JAK inhibitor medications even after six months of treatment.

One significant advantage of JAK inhibitors is their reduced risk of immunological secondary treatment failure.

Unlike some other medications, these oral drugs are less likely to produce adverse immune system responses in patients, making them a viable long-term treatment option.

This study, titled “Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study,” provides strong evidence that JAK inhibitors are effective in treating rheumatoid arthritis, even in real-world scenarios where patients may have diverse health conditions.

This research offers hope to those seeking a more convenient and effective way to manage this chronic autoimmune disease.

If you care about arthritis, please read studies about extra virgin olive oil for arthritis, and pomegranate: A natural treatment for rheumatoid arthritis.

For more information about arthritis, please see recent studies about how to live pain-free with arthritis, and results showing medical cannabis may help reduce arthritis pain, and back pain.

The research findings can be found in Rheumatology.

Follow us on Twitter for more articles about this topic.

Copyright © 2023 Knowridge Science Report. All rights reserved.